Relative Bioavailability
3
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
HutchmedSulfatinib T capsule
AstraZenecaD1400147
AbbVieABT-333
Clinical Trials (3)
Total enrollment: 179 patients across 3 trials
To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers
Start: Apr 2018Est. completion: May 201830 patients
Phase 1Completed
Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions
Start: Feb 2015Est. completion: Jul 2015137 patients
Phase 1Completed
Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects
Start: Nov 2013Est. completion: Dec 201312 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space